COMPANY PROFILE

Rivia

Explore full profile

Unified intelligence layer for clinical trial data and AI agents

Zurich, SwitzerlandFounded 2022Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Rivia

Rivia is a Zurich-based clinical-trial data company building a reusable intelligence layer that unifies fragmented trial data and powers AI-driven operational workflows. Founded by CEO Erik Scalfaro and co-founder Tiago Kieliger, its data engine integrates heterogeneous vendor files in real time, applies trial-specific scientific logic through a library of reusable configurations, and feeds harmonised data into review workflows so biotechs and CROs can detect deviations earlier and act with audit trails. On that foundation Rivia deploys embedded agents such as Spark (natural language to publication-grade clinical visualisations) and agentic data-quality monitoring. Customers cited publicly include Alentis Therapeutics, Calypso Biotech and Abcentra Therapeutics; the company is expanding teams in Zurich and Boston. In March 2026 Rivia raised a $15 million Series A led by Earlybird, with Defiant and existing investors Speedinvest, Amino Collective and Nina Capital, to deepen agentic workflows and scale globally. Sources: Tech.eu 18 Mar 2026; rivia.com.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Zurich, Switzerland
Employees: 29
Open positions: None listed
Dealroom signal: 89.5/100
Industry: Health
Sub-industry: Pharmaceutical, Health Platform
Sector: Biotech & Life Sciences, Data Analytics, Biotechnology, Clinical, Clinical Trials, AI Drug Discovery, Techbio, Techbio Drug Discovery, Digital Pharma, DT and LS
Business model: SaaS
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Mar 2026	$14M	$57M	Speedinvest · Defiant · Amino Collective · Earlybird Venture Capital	↗
SEED✓Equity / VC	Jun 2024	$3.3M	$13M	Speedinvest · Nina Capital · Amino Collective	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Rivia website traffic

Latest recorded traffic for Rivia is 4.7K monthly website visits, down 48.4% over the last three months. Rivia's team grew 45% over the past year.

Latest monthly visits4.7K 3-month web change-48.4% 1-year team growth+45%

Monthly website visitsAug 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CHClimedo HealthOur digital solutions (EDC, ePRO, eCRF and eSurvey) enable you to collect clinical data in a decentralized, automated and secure way. You'll benefit from faster implementation, improved data quality and better patient engagement	Munich, Germany	Operational	27	$6.8M	$22M
INInatoAI-powered patient recruitment	Paris, France	Operational
SSScience4Tech SolutionsUnleashing the power of data and AI for clinical trials	Barcelona, Spain	Operational
LHLindus HealthAccelerates clinical trials for biotech and healthtech pioneers	London, United Kingdom	Operational
NENorthWest E-HealthClinical trial platform, which enables more effective feasibility, economic modeling, recruitment, real-time safety monitoring, and data analytics	Manchester, United Kingdom	Operational
NONovadiscoveryDe-risking technology provider specialized in in silico clinical trials supporting biotech and pharma companies	Lyon, France	Operational
BPBC PlatformsA global leader in providing a powerful data and technology platform for personalized medicine and drug development, accelerating the translation of insights into clinical practice	Zurich, Switzerland	Operational
VEVerisianVerisian accelerates drug time to market with the industry's first platform offering real study traceability (CDISC, SDTM, ADaM, TFLs)	London, United Kingdom	Operational